485 related articles for article (PubMed ID: 26758269)
1. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.
Howard SC; Trifilio S; Gregory TK; Baxter N; McBride A
Ann Hematol; 2016 Mar; 95(4):563-73. PubMed ID: 26758269
[TBL] [Abstract][Full Text] [Related]
2. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
Cheson BD; Heitner Enschede S; Cerri E; Desai M; Potluri J; Lamanna N; Tam C
Oncologist; 2017 Nov; 22(11):1283-1291. PubMed ID: 28851760
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review.
Salter B; Burns I; Fuller K; Eshaghpour A; Lionel AC; Crowther M
Eur J Haematol; 2022 Aug; 109(2):166-181. PubMed ID: 35531791
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
[No Abstract] [Full Text] [Related]
5. Carfilzomib-associated tumor lysis syndrome.
Shely RN; Ratliff PD
Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib-induced tumor lysis syndrome in relapsed multiple myeloma: a report of two cases.
Terzi Demirsoy E; Birtas Atesoglu E; Eren N; Gedük A; Mehtap O; Tarkun P; Hacıhanefioğlu A
Tumori; 2019 Dec; 105(6):NP24-NP27. PubMed ID: 30580656
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
Rao AV; Schmader K
Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
10. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies.
McBride A; Westervelt P
J Hematol Oncol; 2012 Dec; 5():75. PubMed ID: 23237230
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
Ransohoff JD; Kwong BY
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):834-851. PubMed ID: 28918995
[TBL] [Abstract][Full Text] [Related]
12. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice.
Koehler AB; Leung N; Call TG; Rabe KG; Achenbach SJ; Ding W; Kenderian SS; Leis JF; Wang Y; Muchtar E; Hayman SR; Hampel PJ; Finnes HD; Schwager SM; Slager SL; Kay NE; Parikh SA
Leuk Lymphoma; 2020 Oct; 61(10):2383-2388. PubMed ID: 32449401
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
Olin JL; Griffiths CL; Smith MB
J Oncol Pharm Pract; 2018 Oct; 24(7):517-524. PubMed ID: 28696175
[TBL] [Abstract][Full Text] [Related]
15. Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.
Cheson BD
Clin Adv Hematol Oncol; 2009 Apr; 7(4):263-71. PubMed ID: 19521331
[TBL] [Abstract][Full Text] [Related]
16. Tumor lysis syndrome in patients with light chain multiple myeloma: report of two cases.
Chang H; Lee SY; Tang TC
Chang Gung Med J; 2011; 34(6 Suppl):70-5. PubMed ID: 22490464
[TBL] [Abstract][Full Text] [Related]
17. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Kater AP; Kersting S; van Norden Y; Dubois J; Dobber JA; Mellink CH; Evers LM; Croon-de Boer F; Schreurs J; van der Spek E; Visser H; Idink C; Wittebol S; Hoogendoorn M; Tonino SH; Mobasher M; Levin MD;
Blood Adv; 2018 Dec; 2(24):3566-3571. PubMed ID: 30552161
[TBL] [Abstract][Full Text] [Related]
18. Tumor lysis syndrome following single-dose mitoxantrone.
Benekli M; Savaş MC; Güllü IH; Kadayifçi A; Akpek G; Kars A; Güler N; Kansu E; Tekuzman G; Firat D
Chemotherapy; 1995; 41(6):470-2. PubMed ID: 8529438
[TBL] [Abstract][Full Text] [Related]
19. Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment.
Wang L; Jian Y; Yang G; Gao W; Wu Y; Zuo L
Clin J Oncol Nurs; 2015 Feb; 19(1):E4-7. PubMed ID: 25689664
[TBL] [Abstract][Full Text] [Related]
20. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.
Mughal TI; Ejaz AA; Foringer JR; Coiffier B
Cancer Treat Rev; 2010 Apr; 36(2):164-76. PubMed ID: 20031331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
